Coolbrook Named on the 2025 Global Cleantech 100
2025: The Year We Remember the Guardrails Coming Off
Coolbrook, a transformational technology and engineering company, has been named on Cleantech Groups 2025 Global Cleantech 100. This annual list, now in its 16th year, showcases the most promising private cleantech companies making significant contributions to sustainable innovation.
The complimentary report will introduce you to innovators advancing groundbreaking technologies and business models to enable us to act on the ever-increasing climate and environmental crisis.
The cleantech theme is poised for pivotal milestones in 2025 as market forces intensify and innovation accelerates. Continuing trends from 2024, including policy uncertainty, groundbreaking first-of-a-kind (FOAK) projects, and the surging demand for climate adaptation technologies, will emphasize the importance of product and project economics.
Companies that capitalize on organic demand—such as the growing needs of data centers—and prove their technologies in real-world environments without relying on favorable policy support, will find themselves in the best position to succeed. Economic viability will be the defining metric of success in 2025.
"2025 will be remembered as a transformative year for cleantech. The bar has gone up for what kind of level of potential novelty, uniqueness, and cost improvements might be attractive," said Richard Youngman, CEO of Cleantech Group. "The Global Cleantech 100 highlights innovators who are building the foundation for a sustainable and economically viable future."
“Being named in the prestigious 2025 Global Cleantech 100 list is an incredible honor," said Joonas Rauramo, CEO of Coolbrook. “This recognition reflects our steadfast commitment to developing our breakthrough electrification technology that addresses urgent climate challenges. Joining this exceptional group of innovators reinforces our commitment to deliver impactful and economically viable solutions that accelerate heavy industry’s transition to a clean new industrial era.”
Featured companies will be recognized at the Cleantech Forum North America, taking place January 27-29 in San Diego, CA. This event offers participants the opportunity to connect with many of the innovators on the list, along with many other rising stars. The Forum will showcase the latest trends, groundbreaking technologies, and foster collaboration within the cleantech community.
The Global Cleantech 100 program has been running since 2009, the last 12 years with the support of Chubb, the world’s largest property and casualty insurance company.
About Coolbrook:
Hailed as the key technology for industrial decarbonisation globally, Coolbrook is a transformational technology and engineering company on a mission to decarbonise major industrial sectors like petrochemicals and chemicals, iron and steel, and cement. Coolbrook’s revolutionary rotating technology combines space science, turbomachinery and chemical engineering to replace burning of fossil fuels across all major industrial sectors. The technology has two main applications: RotoDynamic Reactor™ (RDR™) to reach 100% CO2 free olefin production, and RotoDynamic Heater™ (RDH™) to provide carbon-free process heating to iron and steel, cement and chemicals production. The RotoDynamic Technology has the potential to reach temperatures of 1700°C and cut 2.4 billion tons (30%) of annual CO2 emissions in heavy industry. For more information, visit www.coolbrook.com.
About Cleantech Group
Cleantech® Group is a research-driven company that helps corporates, public sector, investors and others, identify, assess, and engage with the innovative solutions and opportunities that are related to the world’s massive, and growing, environmental and climate challenges. Our insights and expertise are delivered to clients all over the world through our Research, Consulting, and Events. We have been the leading authority on global cleantech innovation since 2002.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250115529177/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1GLOBAL Empowers Revolut to Offer Mobile Plans in Poland16.12.2025 13:04:00 CET | Press release
1GLOBAL, a technology-driven global mobile communications provider, strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216769985/en/ 1GLOBAL strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. By integrating 1GLOBAL’s eSIM capability into its multi-service app, Revolut’s customers in Poland who signed up to the waitlist can now enjoy bundled mobile plans that include competitively priced domestic data plans starting at zł 25 per month (approx. €6.00 per month) with unlimited calls and texts in Poland and the EU, in just a few taps. For 1GLOBAL, this expansion marks another milestone in the company’s embedded telco services strategy. The services are trusted by more than 4,000 corporate partners across a variety of industries including fi
Dompé Doses First Patients in Europe and US in Phase 3 Studyof Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press release
Atopic keratoconjunctivitis(AKC) is a chronic inflammatory disease of the eye that is frequently associated with atopic conditions, and limited disease awareness often leads to delayed or missed diagnosis. Isocyclosporin is a novel, dual inhibitor oftwo critical immunepathways in ocular inflammation like AKC. Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment
Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration16.12.2025 13:00:00 CET | Press release
With more than $3.5B in annualized stablecoin settlement volume1, Visa brings USDC settlement to U.S. institutions. Visa Inc. (V) today announced the launch of USDC settlement in the United States, marking a major milestone in the company’s stablecoin settlement pilot program and strategy to modernize its settlement layer underpinning global commerce. For the first time, U.S. issuer and acquirer partners can settle with Visa in Circle’s USDC, a fully reserved, dollar-denominated stablecoin. With USDC settlement, issuers can benefit from faster funds movement over blockchains, seven‑day availability and enhanced operational resilience across weekends and holidays - without any change to the consumer card experience. Initial banking participants include Cross River Bank and Lead Bank, which have started settling with Visa in USDC over the Solana blockchain. Broader availability in the U.S. is planned through 2026. Additionally, Visa is a design partner for Arc, a new Layer 1 blockchain d
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release
PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom